ASCO 2023 | KEYNOTE-942: DMFS findings of a personalized mRNA vaccine in melanoma

Adnan Khattak, MBBS, FRACP, Royal Perth Hospital, Perth, Australia, discusses findings from the Phase II KEYNOTE-942 trial (NCT03897881) of mRNA-4157, a novel mRNA-based personalized cancer vaccine, in patients with melanoma. Patients were randomized to either receive the vaccine with pembrolizumab or pembrolizumab alone. The former regimen resulted in superior distant metastasis-free survival (DMFS), highlighting the promising nature of personalized neoantigen vaccines. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.